Acute cardiotoxicity has recently been reported in two patients receiving capecitabine [1, 2] , an oral fluoropyrimidine that undergoes a three-step enzymatic conversion to 5-fluorouracil (5-FU). Cardiotoxicity due to 5-FU is a rare but serious side effect, reported in 1-18% of patients [3] . The most common symptom of fluorouracil-associated cardiotoxicity is anginalike chest pain [3] . Less common symptoms include cardiac arrythmias, congestive heart failure, myocardial infarction, dilatative cardiomyopathy, cardiogenic shock, cardiac arrest or sudden death syndrome. The mechanism of 5-FU-induced cardiotoxicity has not been completely elucidated. Most cases occur during or following initial courses of fluorouracil treatment and are generally reversible on treatment discontinuation. Only a proportion (18%) of patients developing cardiotoxicity following 5-FU exposure have a history of underlying cardiac disease.
To enable a direct comparison between the incidence of cardiotoxic events in patients receiving capecitabine monotherapy (1250 mg/m 2 twice daily, days 1-14, followed by a 7-day rest period) and i.v. 5-FU/LV (Mayo Clinic regimen), a retrospective analysis was performed on two randomized phase III studies comparing the two regimens as first-line therapy for patients with metastatic colorectal cancer (MCRC) (n = 1189) [4, 5] . Two large phase II studies evaluating capecitabine monotherapy in patients with taxane-pretreated metastatic breast cancer (MBC) (n = 236) [6, 7] were also analyzed. This analysis revealed a similar low incidence (3%) of capecitabine-related cardiotoxic events in patients with MCRC and MBC ( Table 1) .
Among patients with MCRC treated in the two phase III trials, 3% of patients in each of the treatment arms experienced treatment-related cardiotoxic events (all grades). Grade 3-4 treatment-related cardiotoxic events occurred in four patients in the 5-FU/LV arm (0.7%) and five patients in the capecitabine arm (0.8%). One fatal cardiac event related to study treatment occurred in each treatment arm. One patient with a prior history of ischaemic heart disease experienced a fatal myocardial infarction while receiving capecitabine, while the second patient experienced cardiac failure 12 days after completion of their 5-FU/LV treatment. Treatment-related cardiotoxic events (all grades) also occurred at a similar incidence (3%) in patients with taxane-pretreated MBC who received capecitabine in two phase II trials (n = 236) [6, 7] . None of the Table 1 . Incidence of treatment-related cardiotoxic adverse events in patients treated in clinical trials evaluating capecitabine monotherapy (1250 mg/m 2 twice daily on days 1-14, followed by a 7-day rest period) a Individual patients may have had ≥1 event. 236 patients treated in these trials experienced serious treatment-related or fatal cardiac events.
In conclusion, these data show that the incidence of cardiotoxicity in patients receiving capecitabine monotherapy is within the range that occurs with 5-FU. Physicians administering any fluoropyrimidine should be aware of the potential for cardiotoxicity and discontinue treatment promptly in patients developing clinical signs of such toxicity.
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